Open AccessCost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Author(s) -
Robert A. Rosenheck
Publication year - 2007
Publication title -
archives of general psychiatry
Language(s) - English
Resource type - Journals
eISSN - 1538-3636
pISSN - 0003-990X
DOI - 10.1001/archpsyc.64.11.1259
Subject(s) - quetiapine , olanzapine , psychiatry , medicine , placebo , risperidone , antipsychotic , randomized controlled trial , quality adjusted life year , psychology , schizophrenia (object oriented programming) , cost effectiveness , risk analysis (engineering) , alternative medicine , pathology
Second-generation antipsychotics (SGAs) are prescribed for psychosis, aggression, and agitation in Alzheimer disease (AD).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom